Tag: cancer

On May 25, 1961, President John F. Kennedy announced, before a special joint session of congress, the dramatic and ambitious goal of sending a...

Adding an inhibitor of ATP-binding cassette (ABC) transporters to sacituzumab govitecan increased the median survival of mice bearing a SN-38-resistant human gastric cancer cell...

Authors: Zarei O, Benvenuti S, Ustun-Alkan F, Hamzeh-Mivehroud M, Dastmalchi S. Title: Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer...

Avacta Life Sciences, the developer of Affimer® biotherapeutics and research reagents will collaborate with Glythera a developer of advanced, stable conjugation chemistries and novel, ultra-potent...

A seemingly healthy patient walks into the doctor’s office for a routine checkup. The doctor says: "I have good news and bad news.  The...

Research published in the November 2014 edition of The FASEB Journal, published by the Federation of the American Societies for Experimental Biology, suggests that a very small single domain antibody called FC5 has proven able to cross the blood-brain barrier (BBB). This opens the door to new treatments for a multitude of brain diseases.

Chronic lymphocytic leukemia or CLL, one of the most common forms of leukemia in Europe and North America, is a disorder of morphologically mature...

Antibody-drug conjugates combine the targeting attributes of antibodies with the cancer destroying properties of drugs that are toxic to cells. Unlike chemotherapy, antibody-drug conjugates specifically seek and destroy cancer cells, with minimal impact on healthy cells.

A study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) being held May 30 - June 3, 2014 in Chicago, Ill, describes the results of a phase I clinical trial of the investigational agent DMOT4039A against pancreatic and ovarian cancers. In this early clinical trial with the goal of identifying possible risks and defining likely dosages, the drug was well tolerated and in some patients showed initial evidence of anti-cancer activity.

Based on trial results from the randomized Phase II PRECEDENT trial for vintafolide (MK-8109/EC145; Merck and Endocyte), an investigational folate small molecule drug conjugate or SMDC, published in the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology, a regulatory application is currently under review with the European Medicines Agency for the treatment of folate-receptor positive platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin (PLD).